Global Patent Index - EP 1045920 A1

EP 1045920 A1 2000-10-25 - NUCLEOTIDE EXPRESSION SYSTEMS WITH REDUCED IMMUNOGENICITY FOR USE IN GENE THERAPY

Title (en)

NUCLEOTIDE EXPRESSION SYSTEMS WITH REDUCED IMMUNOGENICITY FOR USE IN GENE THERAPY

Title (de)

NUKLEOTIDEXPRESSION-SYSTEME MIT VERMINDERTER IMMUNOGENITÄT ZUR VERWENDUNG IN GENTHERAPIE

Title (fr)

SYSTEMES D'EXPRESSION NUCLEOTIDIQUES A IMMUNOGENICITE REDUITE DESTINES A LA THERAPIE GENIQUE

Publication

EP 1045920 A1 (EN)

Application

EP 99901457 A

Priority

  • US 9900733 W
  • US 7140998 P

Abstract (en)

[origin: WO9936562A1] This invention suppresses the immune response to viral or non-viral based methods of gene delivery by incorporating immunosuppressive genes within the gene delivery system. These immunosuppressive genes may be used in addition to a therapeutic treatment or as a therapeutic treatment by themselves.

IPC 1-7 (main, further and additional classification)

C12N 15/86; A61K 48/00; C12N 5/10; C12N 15/34; C12N 15/38

IPC 8 full level (invention and additional information)

C12N 15/09 (2006.01); A61K 31/711 (2006.01); A61K 35/76 (2006.01); A61K 38/16 (2006.01); A61K 48/00 (2006.01); A61P 37/06 (2006.01); C12N 1/15 (2006.01); C12N 1/19 (2006.01); C12N 1/21 (2006.01); C12N 5/10 (2006.01); C12N 15/34 (2006.01); C12R 1/93 (2006.01)

CPC (invention and additional information)

A61K 38/162 (2013.01); A61K 48/00 (2013.01)

Citation (search report)

See references of WO 9936562A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 9936562 A1 19990722; WO 9936562 A9 19990930; AU 2114899 A 19990802; CA 2318664 A1 19990722; EP 1045920 A1 20001025; JP 2002508976 A 20020326

INPADOC legal status


2004-02-04 [18D] DEEMED TO BE WITHDRAWN

- Effective date: 20030801

2000-10-25 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20000718

2000-10-25 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE